Caligan Partners LP Reports New 9.4% Stake in Sensei Biotherapeutics, Inc. (SNSE)

On May 15, 2026, Caligan Partners LP and David Johnson filed a Schedule 13G disclosing a new 9.4% ownership stake in Sensei Biotherapeutics, Inc. (SNSE). The reporting persons beneficially own 126,002 shares of common stock as of the event date of March 31, 2026. This position is held through Caligan Partners Master Fund LP and various managed accounts. In addition to the reported common stock, the reporting persons hold Series B Non-Voting Convertible Preferred Stock that is convertible into an additional 361,010 shares of common stock, subject to certain terms and conditions in the Certificate of Designation. David Johnson, as the Managing Partner of Caligan Partners LP, shares voting and dispositive power over the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The calculation of the ownership percentage is based on 1,340,281 shares of common stock outstanding as of March 23, 2026.